There are 11 papers on plateletcrit in aging research: 11 observational studies in people.
11 papers study it2 more mention it4 findings
1 new paper in 30 daysSee all 13 papers on plateletcrit
“PCT and PDW showed relatively stronger associations with MetS (PCT: Q4 vs Q1, aOR = 1.85, 95% CI: 1.81-1.89;”
- Humans11
Effects
1Telomere length
mediatesin humans1
1 study
Telomere length
mediatesin humans1
Plateletcrit is linked with telomere length in humans (association between central obesity indices and aging biomarkers) (2.85% to 10.10%).
Humansassociation between central obesity indices and aging biomarkersn = 5,091
Associations
3Motoric cognitive risk syndrome
upin humans1OR 1.13
1 study
Motoric cognitive risk syndrome
upin humans1OR 1.13
Plateletcrit is associated with motoric cognitive risk syndrome in humans after adjustment for potential confounders (OR 1.13, 95% CI 1.01 to 1.26).
Humansafter adjustment for potential confoundersn = 4,080
Metabolic syndrome
upin humans1
1 study
Metabolic syndrome
upin humans1
Plateletcrit is associated with metabolic syndrome in humans (Q4 versus Q1; multivariable adjusted) (aOR 1.85, 95% CI 1.81–1.89; Q4 versus Q1).
HumansQ4 versus Q1; multivariable adjustedn = 570,000
Hepatocellular carcinoma
downin humans1OR 0.57
1 study
Hepatocellular carcinoma
downin humans1OR 0.57
Plateletcrit is linked with a lower risk of hepatocellular carcinoma in humans (conditional logistic regression with matched controls) (OR 0.57 (95% CI 0.42–0.78)).
Humansconditional logistic regression with matched controls